» Articles » PMID: 28760153

An Overview of Forensic Drug Testing Methods and Their Suitability for Harm Reduction Point-of-care Services

Overview
Journal Harm Reduct J
Publisher Biomed Central
Specialties Pharmacology
Psychiatry
Date 2017 Aug 2
PMID 28760153
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.

Citing Articles

Field-Portable Device for Detection of Controlled and Psychoactive Substances from e-Cigarettes.

Gardner M, Bowden C, Manzoor S, Cozier G, Andrews R, Craft S ACS Omega. 2025; 10(8):7839-7847.

PMID: 40060840 PMC: 11886666. DOI: 10.1021/acsomega.4c08614.


Biomarkers and point of care screening approaches for the management of preeclampsia.

Ng K, Chaturvedi N, Cote G, Fisher S, Mabbott S Commun Med (Lond). 2024; 4(1):208.

PMID: 39433973 PMC: 11493996. DOI: 10.1038/s43856-024-00642-4.


Implementation of a community-based LC-UV drug checking service: promising preliminary findings on feasibility and validity.

Fabresse N, Papias E, Heckenroth A, Martin V, Allemann D, Roux P Harm Reduct J. 2024; 21(1):185.

PMID: 39425213 PMC: 11488248. DOI: 10.1186/s12954-024-01098-4.


Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study.

Park J, Serafinski R, Ujeneza M, McKenzie M, Tardif J, Krotulski A Drug Alcohol Depend Rep. 2024; 11:100247.

PMID: 38974777 PMC: 11225690. DOI: 10.1016/j.dadr.2024.100247.


How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives.

Moran L, Ondocsin J, Outram S, Ciccarone D, Werb D, Holm N Harm Reduct J. 2024; 21(1):92.

PMID: 38734643 PMC: 11088080. DOI: 10.1186/s12954-024-01014-w.


References
1.
Verkouteren J, Staymates J . Reliability of ion mobility spectrometry for qualitative analysis of complex, multicomponent illicit drug samples. Forensic Sci Int. 2010; 206(1-3):190-6. DOI: 10.1016/j.forsciint.2010.08.005. View

2.
Brunt T, Nagy C, Bucheli A, Martins D, Ugarte M, Beduwe C . Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project. Drug Test Anal. 2016; 9(2):188-198. DOI: 10.1002/dta.1954. View

3.
Mounteney J, Griffiths P, Sedefov R, Noor A, Vicente J, Simon R . The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction. 2015; 111(1):34-48. DOI: 10.1111/add.13056. View

4.
ONeal C, CROUCH D, Fatah A . Validation of twelve chemical spot tests for the detection of drugs of abuse. Forensic Sci Int. 2000; 109(3):189-201. DOI: 10.1016/s0379-0738(99)00235-2. View

5.
Brown J, Malone M . Some U.S. street drug identification programs. J Am Pharm Assoc. 1973; 13(12):670-4. DOI: 10.1016/s0003-0465(16)32815-4. View